Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

Molecular heterogeneity of triple-negative breast cancer and its clinical implications

(2011) Sheeba Irshad et al.   CURRENT OPINION IN ONCOLOGY

Aneuploidy Drives a Mutator Phenotype in Cancer

(2011) R. D. Kolodner et al.   SCIENCE

Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma

(2010) Hermien Hartog et al.   BREAST CANCER RESEARCH AND TREATMENT

Use of standard markers and incorporation of molecular markers into breast cancer therapy

(2010) Manfred Kaufmann et al.   CANCER

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

(2010) Mothaffar F. Rimawi et al.   CANCER

Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States

(2009) Dezheng Huo et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

(2008) M. F. Press et al.   CLINICAL CANCER RESEARCH

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

How basal are triple-negative breast cancers?

(2008) François Bertucci et al.   INTERNATIONAL JOURNAL OF CANCER